Abstracts tagged "Eye Disorders"

Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Ilaria Maccora¹, Mekibib Altaye², Tiffany Nguyen³, Kenneth Greis⁴, Wendy Haffey⁴, Theresa Hennard⁵, Alyssa Sproles², Sherry Thornton², Virginia Miraldi Utz⁵ and Sheila Angeles-Han², ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…
Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 0501 • ACR Convergence 2023
Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
Nikolaos Kougkas¹, Konstantina Magiouf², Chrysoula Gialouri³, Gerasimos Evangelatos⁴, Maria Pappa², Afroditi Mpitouli⁵, Alexios Iliopoulos⁶, Theodoros Dimitroulas⁷, Anastasios Karamanakos⁸, Aikaterini Dimouli⁸, Maria Tektonidou², Petros Sfikakis⁹ and George Fragoulis¹⁰, ¹4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki, Thessaloniki, Greece, ²Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³National and Kapodistrian University of Athens, Zografou, Greece, ⁴Rheumatology Department, 417 Army Share Found Hospital (NIMTS), Athens, Greece, ⁵Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁶NIMTS Veterans Hospital, Zografou, Greece, ⁷Aristotle University of Thessaloniki - School of Medicine, Thessaloniki, Greece, ⁸“Evangelismos” General Hospital, Rheumatology Department, Athens, Greece, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁰"Laiko" Hospital - First Department of Propaedeutic and Internal Medicine, Athens, Greece
Background/Purpose: Data are still scarce about risk factors predicting the occurrence and course of uveitis in spondyloarthritis (SpA). We aimed to examine associations between demographic,…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0524 • ACR Convergence 2023
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Nigil Haroon¹, Zeynep Baskurt², Tina Chim³, Robert Inman⁴, Diana Paez⁵, Thomas Kumke⁶, Rachel Tham⁷, Mindy Kim⁸, Irene van der Horst-Bruinsma⁹ and Lianne Gensler¹⁰, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ²Department of Biostatistics, University Health Network, Toronto, ON, Canada, ³University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Atlanta, GA, ⁹Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁰University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting more than a third of patients. However, long-term interventional…
Abstract Number: 2550 • ACR Convergence 2023
The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
Zijing Yang¹, Maryam Adas¹, Bechman Katie¹, Deepak Nagra¹, Ali Soykan Uguzlar¹, Mark Russell¹, Nicky Wilson², Sophia Steer¹, Sam Norton¹ and James Galloway¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
Abstract Number: 1062 • ACR Convergence 2023
Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Samuel Good¹, Grazyna Adamus², Michael Gorin³, Jordan Jacquez¹, Jennifer Grossman¹, Brian Skaggs¹, Ashira Hasan² and Maureen McMahon⁴, ¹University of California Los Angeles, Los Angeles, CA, ²Oregon Health & Science University, Portland, OR, ³Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Autoimmune retinopathy (AIR) is a disease process in which circulating autoantibodies (AAbs) against retina-specific antigens cause local inflammation and can lead to blindness. Hydroxychloroquine…
Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Maria Salgado Guerrero¹ and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…
Abstract Number: 1127 • ACR Convergence 2023
Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Maria Paula Alvarez Hernandez¹, Inés Pérez Sancristóbal¹, Alfredo Madrid García², Lara Borrego Sanz³, Cristina Hormigos martín¹, Beatriz García Tirado³, Mayte Ariño Gutiérrez³, Cristina lajas Petisco¹, Pedro Arriola Villalobos³, Esperanza Pato Cour³ and Luis Rodríguez Rodríguez¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIU) are characterized by inflammation of the middle layer of the eye wall and have a significant impact on patients' visual-related quality…
Abstract Number: 1130 • ACR Convergence 2023
Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI
Esperanza Pato¹, Lara Borrego-Sanz², Marta Domínguez³, Fernando Alonso⁴, Fayna Rodríguez-Gonazález⁵, Marta Tejera-Santana⁵, María del Mar Esteban-Ortega⁶, Isabel García-Lozano⁷, Lucia Martinez-Costa⁸, Samuel Gonzalez-Ocampo⁸, Maite Sainz de la Maza⁹, Aina Moll-Udina⁹, Zulema Plaza¹⁰, Alejandro Fonollosa-Calduch¹¹, Joseba Artaraz¹¹, Teresa Díaz-Valle¹², María Gurrea-Almela¹², David Diaz-Valle¹³ and Rosalía Méndez-Fernández¹³, ¹Hospital Clínico San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Ophthalmology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Hospital Doctor Negrín, Ophthalmology, Gran Canaria, Spain, ⁶Hospital Infanta Sofia, Madrid, Spain, ⁷Hospital Infanta Sofia, Ophthalmology, Madrid, Spain, ⁸Hospital Doctor Peset, Ophthalmology, Valencia, Spain, ⁹Hospital Clinic of Barcelona, Ophthalmology, Barcelona, Spain, ¹⁰Universidad Autónoma de Madrid, Madrid, Spain, ¹¹Hospital de Cruces, Ophthalmology, Bilbao, Spain, ¹²Hospital De Móstoles, Ophthalmology, Madrid, Spain, ¹³Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Standardized and validated outcome measures of disease activity are lacking in the treatment and assessment of uveitis, making it difficult to compare efficacy and…
Abstract Number: 1220 • ACR Convergence 2023
Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)
Denise Kruzikas¹, Ann Eldred², Shelly Kafka³, Janet Church⁴, Katherine Hammitt⁴, Patricia Koochaki⁵ and Christina O'Donnell⁶, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Inc., Lake Bluff, IL, ³AbbVie, Inc., Norristown, PA, ⁴Sjögren’s Foundation, Reston, VA, ⁵ICON Clinical Research LLC, Raleigh, NC, ⁶ICON plc, Raleigh, NC
Background/Purpose: Dry eye is one of the most important and prevalent symptoms experienced by patients with Sjögren's Disease (SJD). The DED-SQ is a 12-item patient…
Abstract Number: 119 • 2023 Pediatric Rheumatology Symposium
Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis
Kaleo Ede¹, Michael Shishov², Elisa Wershba², Nikita Goswami², Sabrina Gorry², Malin Jospeh², Lucia Mirea² and James O'neil², ¹Phoenix Children's Hosptial; University of Arizona College of Medicine- Phoenix, Phoenix, AZ, ²Phoenix Children's Hospital, Phoenix, AZ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood, affecting 1 to 22 per 100,000 children. JIA-associated uveitis is known…
Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium
Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Catherine Lavallee¹, Sabrina Gmuca² and Melissa Lerman², ¹Virginia Tech Carilion School of Medicine, ROANOKE, VA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: 017 • 2023 Pediatric Rheumatology Symposium
Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study
Tiffany Nguyen¹, Ilaria Maccora¹, Mekibib Altaye¹, Wendy Haffey², Theresa Hennard¹, Alyssa Sproles¹, Sherry Thornton¹, Virginia Miraldi Utz¹, Ken Greis² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH
Background/Purpose: Children diagnosed with oligoarticular juvenile idiopathic arthritis (JIA), the most commonly diagnosed subset of chronic arthritis, are at increased risk of developing uveitis. Known…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].